Currently out of the existing stock ratings of Michael King, 107 are a BUY (98.17%), 2 are a HOLD (1.83%).

Michael King

Work Performance Price Targets & Ratings Chart

Analyst Michael King, carries an average stock price target met ratio of 44.36% that have a potential upside of 30.21% achieved within 152 days. Previously, Michael King worked at HCWAINWRIGHT.

Michael King’s has documented 206 price targets and ratings displayed on 23 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SONN, Sonnet Biotherapeutics Holdings at 22-Aug-2023.

Wall Street Analyst Michael King

Analyst best performing recommendations are on BMEA (BIOMEA FUSION).
The best stock recommendation documented was for BMEA (BIOMEA FUSION) at 3/24/2023. The price target of $22 was fulfilled within 4 days with a profit of $6.57 (42.58%) receiving and performance score of 106.45.

Average potential price target upside

of $790.69 (69.1%) on KTRA (KINTARA THERAPEUTICS).
of $163.63 (25.97%) on REGN (REGENERON PHARMACEUTICALS).
of $110.33 (71.65%) on CALA (CALITHERA BIOSCIENCES).

ALNY Alnylam Pharmaceuticals LTRN Lantern Pharma AGIO Agios Pharm ANAB AnaptysBio CELG Celgene COGT Cogent Biosciences EXEL Exelixis INFI Infinity Pharmaceuticals KTRA Kintara Therapeutics NTLA Intellia Therapeutics REGN Regeneron Pharmaceuticals AGEN Agenus BMEA Biomea Fusion CMPX Compass Therapeutics VINC Vincerx Pharma XNCR Xencor SONN Sonnet Biotherapeutics Holdings JSPR Jasper Therapeutics CALA Calithera Biosciences HOWL Werewolf Therapeutics SYRS Syros Pharmaceuticals SLRX Salarius Pharmaceuticals IDRA Idera Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Paul Matteis (STIFEL)